PMID- 33063270
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201112
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 11
IP  - 12
DP  - 2020 Dec
TI  - Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 
      Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring.
PG  - 2945-2958
LID - 10.1007/s13300-020-00940-9 [doi]
AB  - INTRODUCTION: Sodium-glucose cotransporter 2 (SGLT2) inhibitors promote urinary 
      glucose excretion. However, the differences in the effects of various SGLT2 
      inhibitors are unknown. We used flash glucose monitoring (FGM) to identify the 
      differences between tofogliflozin and ipragliflozin in terms of efficacy in 
      reducing glycemic variability and mitigate hypoglycemia risk. METHODS: In this 
      crossover study, 24 patients with type-2 diabetes mellitus (T2DM) receiving 
      insulin glargine U300 therapy were randomly allocated to tofogliflozin and 
      ipragliflozin or ipragliflozin and tofogliflozin group. Glycemic variability and 
      hypoglycemia were compared using to the 3-day FGM data per treatment period. 
      RESULTS: Glucose level 2 h after each meal was significantly lower with 
      tofogliflozin administration than with ipragliflozin administration. Time below 
      the target glucose range after tofogliflozin administration was significantly 
      lower than that after ipragliflozin administration (2.1% +/- 4.4% vs. 
      8.7% +/- 11.7%). The 24-h standard deviation of glucose level, mean amplitude of 
      glycemic excursion, and mean percent time with nocturnal hypoglycemia after 
      tofogliflozin administration were significantly lower than those after 
      ipragliflozin administration. CONCLUSIONS: Tofogliflozin was more effective and 
      safer than ipragliflozin in reducing glycemic variability and mitigating 
      hypoglycemia risk in patients with T2DM treated with insulin glargine U300. TRIAL 
      REGISTRATION: This trial was registered at the University Hospital Medical 
      Information Network Clinical Trial Registry (no. UMIN000037158).
FAU - Kawaguchi, Yuji
AU  - Kawaguchi Y
AD  - Department of Internal Medicine, Minami Osaka Hospital, 1-18-18, Higashikagaya, 
      Suminoe-ku, Osaka, 559-0012, Japan. y.kawaguchi@minamiosaka.com.
FAU - Sawa, Jun
AU  - Sawa J
AD  - Department of Internal Medicine, Minami Osaka Hospital, 1-18-18, Higashikagaya, 
      Suminoe-ku, Osaka, 559-0012, Japan.
FAU - Kumeda, Yasuro
AU  - Kumeda Y
AD  - Department of Internal Medicine, Minami Osaka Hospital, 1-18-18, Higashikagaya, 
      Suminoe-ku, Osaka, 559-0012, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC7644607
OTO - NOTNLM
OT  - Glycemic variability
OT  - Hypoglycemia
OT  - Tofogliflozin
EDAT- 2020/10/17 06:00
MHDA- 2020/10/17 06:01
PMCR- 2020/10/15
CRDT- 2020/10/16 05:59
PHST- 2020/08/01 00:00 [received]
PHST- 2020/10/01 00:00 [accepted]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2020/10/17 06:01 [medline]
PHST- 2020/10/16 05:59 [entrez]
PHST- 2020/10/15 00:00 [pmc-release]
AID - 10.1007/s13300-020-00940-9 [pii]
AID - 940 [pii]
AID - 10.1007/s13300-020-00940-9 [doi]
PST - ppublish
SO  - Diabetes Ther. 2020 Dec;11(12):2945-2958. doi: 10.1007/s13300-020-00940-9. Epub 
      2020 Oct 15.